Karin Walker
Director/Board Member at CYCLACEL PHARMACEUTICALS, INC.
Net worth: 11 106 $ as of 2024-05-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Paul McBarron | M | 63 | 22 years | |
| Christopher Henney | M | 83 | 18 years | |
| Brian Schwartz | M | 52 | 4 years | |
| Gene Kinney | M | 55 | 12 years | |
| Daniel Welch | M | 66 | - | |
| Spiro Rombotis | M | 65 | 27 years | |
| Lars Ekman | M | 74 | 12 years | |
| Tran Nguyen | M | 50 | 11 years | |
| Richard Collier | M | 70 | 12 years | |
| Samuel Barker | M | 81 | 10 years | |
| Michael J. Malecek | M | 58 | 5 years | |
| Randy Fawcett | M | - | - | |
| Paula Cobb | F | 51 | 5 years | |
| Wagner M. Zago | M | 51 | 12 years | |
| Brandon Smith | M | 50 | 4 years | |
| Oleg Nodelman | M | 47 | 5 years | |
| Robert Spiegel | M | 73 | 6 years | |
| Shane Cooke | M | 61 | 12 years | |
| Dennis Selkoe | M | 80 | 11 years | |
| Kenneth Ferguson | M | 68 | 2 years | |
| Yvonne M. Tchrakian | F | - | 10 years | |
| Hideki Garren | M | 60 | 3 years | |
| Carol Karp | F | 71 | 8 years | |
| Helen Kim | F | 61 | 2 years | |
| Michael Bachner | M | - | 2 years | |
| William Dunn | M | 54 | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Louis Lange | M | 72 |
CV Therapeutics, Inc.
 CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 19 years |
| Geoff Duyk | M | 64 | 18 years | |
| Arthur Levinson | M | 73 | 4 years | |
| Nicholas Khadder | M | 50 | 6 years | |
| Jonas Grossman | M | 50 | 2 years | |
| Dale B. Schenk | M | 66 | 4 years | |
| Andrew McDonald | M | 50 | 1 years | |
| Samir Kaul | M | 50 | 6 years | |
| Carole Piwnica | F | 66 | 12 years | |
| Patrick Pichette | M | 61 | 3 years | |
| Karl Härfstrand | M | 66 | 9 years | |
| Arthur William Homan | M | 64 | 5 years | |
| Gary Loeb | M | 54 | 2 years | |
| Michael Rice | M | 59 | 1 years | |
| Sanjiv Patel | M | 50 | 2 years | |
| Jennifer Zibuda | F | - | 3 years | |
| David Dobkin | M | 45 | 1 years | |
| John Steven Ziegler | M | 65 | - | |
| Barry Dennis | M | 59 | - | |
| Kenneth Lee | M | 76 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 7 years |
| Tamara L. Tompkins | F | 59 | 7 years | |
| Nam Hai Chua | M | 79 | - | |
| Judy Chiao | M | 64 | 17 years | |
| Tara Nickerson | M | 51 | 6 years | |
| Abdullah bin Khalifa Al Thani | M | 63 | 7 years | |
| Joseph M. Davie | M | 84 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 3 years |
| Caryn McDowell | F | 54 | 1 years | |
| Martin Koller | M | 73 | 4 years | |
| Joel Velasco | M | - | - | |
| Krishna R. Polu | M | 50 | 4 years | |
| Sarah Noonberg | M | 56 | 1 years | |
| Cynthia Smith | F | 55 | 5 years | |
| James Young Richardson | M | 57 | - | |
| Radhika Tripuraneni | M | 44 | 4 years | |
| David B. Mcninch | M | 55 | - | |
| Rebecca Lucia | F | 52 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 1 years |
| Mary Ellen Sillivos | F | - | 7 years | |
| Peter M. Strumph | M | 59 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 10 years |
| Matthew Panuwat | M | 47 | 1 years | |
| Jason Raleigh | M | 47 | 5 years | |
| Amartya Basu | M | - | 3 years | |
| Courtney Phillips | F | 49 | 2 years | |
| Louis Yu | M | 73 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 1 years |
| Jeffrey H. Knapp | M | 58 | 7 years | |
| Peter P. Boynton | M | 69 | - | |
| Kenneth F. Boehm | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 4 years |
| Thomas Shenk | M | 77 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 5 years |
| Robert F. Venteicher | M | 78 | 6 years | |
| Peter Hutt | M | 89 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 8 years |
| David C. McCaleb | M | 70 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 10 years |
| Peter G. Milner | M | 68 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 17 years |
| Dan Spiegelman | M | 65 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 11 years |
| Thomas L. Gutshall | M | 85 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 15 years |
| Barbara McNeil | M | 83 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 14 years |
| Anne-Marie S. Duliege | M | 64 | 9 years | |
| Anne Champsaur | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 3 years |
| Douglas T. Sheehy | M | 57 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 5 years |
| Steven Mills | M | 68 | 1 years | |
| Shay Weisbrich | F | 71 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 1 years |
| Jennifer Hodge | F | 55 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 7 years |
| Bruce Philip Pritchard | M | 51 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 2 years |
| Mario Neutel Soares Portela | M | 62 | 3 years | |
| Michael T. Sweeney | M | 63 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 4 years |
| Philip Wells | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 1 years |
| David Banks | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 4 years |
| Jeryl Hilleman | F | 67 | 4 years | |
| Santo Costa | M | 78 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 8 years |
| Huang I-Zu | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 6 years |
| Mark Kirschbaum | M | 63 | 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 65 | 68.42% |
| Ireland | 31 | 32.63% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Karin Walker
- Personal Network
